The Vascular Disease Foundation is pleased to announce its corporate membership program — the Vascular Disease Foundation's Corporate Roundtable.
The goal of the Corporate Roundtable is to reduce the mortality and morbidity from vascular diseases. The Roundtable is allied with the Foundation in the belief that patient quality of life and longevity can be improved through education and prevention, prompt diagnosis, comprehensive treatment and effective rehabilitation of arterial and venous disease.
The Corporate Roundtable provides a forum for dialog between industry and the nation’s top thought leaders in the vascular arena. Formal communications will occur during two face-to-face meetings and at least one conference call where member organizations discuss critical issues in vascular disease and the challenges of educating the public and healthcare providers about them. In addition, there is an open door policy for Roundtable members who are encouraged to reach out to the Foundation’s executive staff on a regular basis with questions and ideas.
Roundtable members brainstorm and strategize with the Foundation’s leadership on how to elevate the national conversation and concern about vascular disease in general, and specifically PAD and DVT/PE, with diabetic related conditions to follow soon. Members have specific opportunities to participate in work groups for peripheral artery disease and/or venous disease, and to join either the P.A.D. Coalition or the Venous Disease Coalition where they can become active in advocacy, education and awareness efforts.
To learn more about the National Corporate Roundtable, or to inquire about membership, please send us an e-mail. And please visit our members' websites to learn more about them.
Medtronic |
AstraZeneca |
Thanks to our 2011 members:
Bristol Myers Squibb/Sanofi-Aventis |
Cook Medical |
Cordis Endovascular |
Abbott Vascular |
AngioDynamics |
AstraZeneca |
Bard Peripheral Vascular |
ev3 |
W.L. Gore & Associates |
SIGVARIS |
UNETIXS Inc. |
BioMedix |
Endovascular Today |